Cetuximab Therapy and Symptomatic Hypomagnesemia
نویسندگان
چکیده
منابع مشابه
Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
BACKGROUND Hypomagnesemia is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the incidence and risk factors of hypomagnesemia in head and neck cancer patients treated with Cmab. METHODS We retrospectively reviewed 131 head and neck cancer patients who received Cmab-containing therapy. Main eligibility criteria were ≥3 Cmab administrations, no p...
متن کاملIncidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis
Hypomagnesemia is a serious adverse event for patients treated with cetuximab, an inhibitor of endothelial growth factor receptor (EGFR). However, no significant association has yet been established between cetuximab and hypomagnesemia in randomized controlled clinical trials (RCTs). The present study conducted a systematic review and meta-analysis of published RCTs to assess the overall risk o...
متن کاملMeta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.
BACKGROUND Cetuximab is often used in patients with colorectal cancer, head and neck cancer, and other cancers. Hypomagnesemia is a major adverse event that was often ignored in studies. The aim of this meta-analysis is to gain a better understanding of the overall incidence and risk of hypomagnesemia in patients who received cetuximab-based therapy. METHODS Databases, including Pubmed, EMBAS...
متن کاملAXL mediates resistance to cetuximab therapy.
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical outcome. In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where ...
متن کاملA patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea: a case report
INTRODUCTION Metformin is licensed for treatment of diabetes mellitus type 2. This report describes a patient on metformin who developed diarrhoea and symptomatic hypomagnesemia. To the author's knowledge, this is the first report on metformin-induced symptomatic hypomagnesemia. CASE PRESENTATION The patient was a 57-year old Caucasian male with diabetes mellitus type 2. He had been on metfor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2005
ISSN: 1460-2105,0027-8874
DOI: 10.1093/jnci/dji242